Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | New Therapeutic Strategy Targets Dengue Virus Using Artificial microRNAsNew Therapeutic Strategy Targets Dengue Virus Using Artificial microRNAs New Rochelle, NY—Mosquito- Pei-wen Xie, Yu Xie, Xiu-juan Zhang, Hai Huang, Li-na He, Xue-jun Wang, and Sheng-qi Wang, Beijing Institute of Radiation Medicine and Second Artillery General Hospital, Beijing, and Central South University, Changsha, China, identified multiple regions in the dengue virus genome that have maintained the same nucleic sequence over long periods of evolution. These highly conserved regions are ideal targets for antiviral drug development as they are unlikely to mutate and allow the virus to develop drug resistance. In the article "Inhibition of Dengue Virus 2 Replication by Artificial MicroRNAs Targeting the Conserved Regions," (http://online.liebertpub.com/ “The dengue virus is endemic in over 100 countries and spreading rapidly," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. “In the absence of effective preventive measures, new treatments like those being pursued by Xie et al. are desperately needed.” Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in- About the Journal Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/ About the Society The Oligonucleotide Therapeutics Society (http://www.oligotherapeutics.org) is an open, nonprofit forum to foster academia and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and Human Gene Therapy Methods, Genetic Testing and Molecular Biomarkers, ASSAY and Drug Development Technologies, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|